Emmanuel Abate, president genomic medicine and head of sustainability, Cytiva explores how bioprocessing leaders can protect patients, the planet, and their supply chain.
PFAS continues to draw heightened attention from regulators, customers, and the public. As proposals to restrict usage advance across global markets, the bioprocessing industry is being asked to demonstrate responsible stewardship, while ensuring uninterrupted access to essential therapies. The challenge is navigating an issue that is both scientifically complex and deeply operational. How do we advance environmental progress without disrupting the supply of lifesaving medicines?